AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting riskPopularity #3,846

HRTX · NASDAQ · Biotechnology

Heron Therapeutics (HRTX)

Sells U.S. hospital injectables for postsurgical pain and nausea prevention.

$0.2940

vs last close−0.01 (−1.67%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	31	34	35	36	33	41	39	37	38	41	35	38
Cost of revenue	18	10	8	11	9	10	8	10	15	8	11	12
Gross profit	13	24	26	26	23	31	30	27	23	33	24	26
	38	35	31	32	28	26	27	29	27	33	29	28
Research & development	14	11	5	4	4	3	2	3	3	4	2	3
	25	24	26	28	23	23	25	26	27	26	26	25
Selling & marketing	13	12	11	14	11	11	12	12	13	12	14	14
General & administrative	12	11	15	14	12	12	13	14	14	13	12	11
Other expenses	0	0	0	0	0	0	0	0	−3	3	0	0
Operating income	−25	−10	−5	−6	−4	4	3	−2	−4	0	−5	−2
	0	−1	2	−3	0	−1	−1	−1	−13	−3	−3	−3
Interest income	0	2	0	0	0	0	0	0	0	0	0	0
Interest expense	1	2	1	0	1	4	1	0	3	1	0	0
Other non-operating income	0	−4	−2	2	0	−4	0	1	11	2	3	3
Income before tax	−25	−11	−3	−9	−5	4	3	−2	−17	−3	−8	−5
Net income from continuing operations	−25	−11	−3	−9	−5	4	3	−2	−17	−3	−8	−5
Net income	−25	−11	−3	−9	−5	4	3	−2	−17	−3	−8	−5
EPS, basic	−$0.17	−$0.07	−$0.02	−$0.06	−$0.03	$0.02	$0.02	−$0.02	−$0.10	−$0.02	−$0.04	−$0.03
EPS, diluted	−$0.17	−$0.07	−$0.02	−$0.06	−$0.03	$0.02	$0.02	−$0.02	−$0.10	−$0.02	−$0.04	−$0.03
Weighted average shares, basic	145	150	151	152	153	153	153	154	170	167	190	190
Weighted average shares, diluted	145	150	151	152	153	153	153	154	170	167	190	190
EBITDA	−24	−6	−2	−8	−4	9	4	−2	−14	−1	−8	−5
Depreciation & amortization	1	1	1	1	1	1	1	1	1	1	1	0
EBIT	−25	−6	−3	−9	−4	8	3	−2	−15	−2	−8	−5